News Conference News ESC 2013 Symplicity Studies Support Safety, Efficacy of Percutaneous Renal Denervation Caitlin E. Cox September 04, 2013
News Conference News ESC 2013 AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction Caitlin E. Cox September 04, 2013
News Conference News ESC 2013 PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk Yael L. Maxwell September 04, 2013
News Conference News ESC 2013 Usefulness of IABP Questioned in MI Patients with Cardiogenic Shock Yael L. Maxwell September 03, 2013
News Conference News ESC 2013 BIC-8: Positive Signs for Early-Rule Out of Suspected ACS Using Copeptin Caitlin E. Cox September 03, 2013
News Conference News ESC 2013 New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups Caitlin E. Cox September 03, 2013
News Conference News ESC 2013 CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis Yael L. Maxwell September 03, 2013
News Industry News Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System September 03, 2013
News Conference News ESC 2013 PROMISE: Intracoronary Adenosine Effective in STEMI Patients with Shorter Ischemic Times September 03, 2013
News Conference News ESC 2013 FRANCE 2: Post-TAVR Aortic Regurgitation Doubles Mortality Risk Caitlin E. Cox September 02, 2013